Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VARIVAX New Seed Process with concomitant M-M-R II in toddlers
2017-001444-35Phase 3
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varicella virus vaccine live and M-M-R II in chickenpox (2 arms), sponsored by Merck & Co. Primary endpoints: Non-inferiority of VZV antibody response at 6 weeks after dose 1 and Safety and tolerability of first and second doses.
02
Drugs
varicella virus vaccine liveM-M-R II
03
Conditions
chickenpox
Beyond the preview
Go deeper on 2017-001444-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001444-35.